Literature DB >> 27900642

Ischemia burden on stress SPECT MPI predicts long-term outcomes after revascularization in stable coronary artery disease.

Hendrik J Boiten1, Jan C van den Berge2, Roelf Valkema3, Ron T van Domburg2, Felix Zijlstra2, Arend F L Schinkel2.   

Abstract

BACKGROUND: It is not entirely clear whether ischemia burden on stress single-photon emission computed tomography (SPECT) effectively identifies patients who have a long-term benefit from coronary revascularization.
METHODS: The study population consisted of 719 patients with ischemia on stress SPECT. Early coronary revascularization was defined as percutaneous coronary intervention or coronary artery bypass grafting ≤90 days after SPECT. Patients who underwent late revascularization (>90 days after SPECT) were excluded (n = 164).
RESULTS: Of the 538 patients (73% men, mean age 59.8 ± 11 years), 348 patients had low ischemia burden (<3 ischemic segments) and 190 patients had moderate to high ischemia burden (≥3 ischemic segments). A total of 76 patients underwent early revascularization. During a median follow-up of 12 years (range 4-17), 283 patients died of whom 125 due to cardiac causes. Early revascularization was beneficial on all-cause mortality (HR 0.46, 95% CI 0.30-0.46) and cardiac mortality (HR 0.54, 95% CI 0.29-0.99).
CONCLUSIONS: Patients with myocardial ischemia on stress SPECT who underwent early revascularization had a lower all-cause mortality and cardiac mortality during long-term follow-up as compared to patients who received pharmacological therapy alone. This difference in long-term outcomes was mainly influenced by the survival benefit of early revascularization in the patients with moderate to high ischemia burden.

Entities:  

Keywords:  Early revascularization; SPECT; ischemia; long-term

Mesh:

Year:  2016        PMID: 27900642     DOI: 10.1007/s12350-016-0735-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  13 in total

1.  Benefit of revascularization for stable ischaemic heart disease: the jury is still out.

Authors:  Amir-Ali Fassa; William Wijns; Philippe Kolh; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2013-01-29       Impact factor: 29.983

2.  2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; James C Blankenship; Karen P Alexander; John A Bittl; John G Byrne; Barbara J Fletcher; Gregg C Fonarow; Richard A Lange; Glenn N Levine; Thomas M Maddox; Srihari S Naidu; E Magnus Ohman; Peter K Smith
Journal:  Circulation       Date:  2014-07-28       Impact factor: 29.690

3.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

4.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

5.  Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.

Authors:  Leslee J Shaw; William S Weintraub; David J Maron; Pamela M Hartigan; Rory Hachamovitch; James K Min; Marcin Dada; G B John Mancini; Sean W Hayes; Robert A O'Rourke; John A Spertus; William Kostuk; Gilbert Gosselin; Bernard R Chaitman; Merill Knudtson; John Friedman; Piotr Slomka; Guido Germano; Eric R Bates; Koon K Teo; William E Boden; Daniel S Berman
Journal:  Am Heart J       Date:  2012-08       Impact factor: 4.749

6.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction.

Authors:  R Hachamovitch; D S Berman; L J Shaw; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

7.  Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography.

Authors:  Rory Hachamovitch; Sean W Hayes; John D Friedman; Ishac Cohen; Daniel S Berman
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

9.  Prediction of 8-year cardiovascular outcomes in patients with systemic arterial hypertension: value of stress (99m)Tc-tetrofosmin myocardial perfusion imaging in a high-risk cohort.

Authors:  Marisa C G Tjong Joe Wai; Machiel J M Ottenhof; Hendrik J Boiten; Roelf Valkema; Ron T van Domburg; Arend F L Schinkel
Journal:  J Nucl Cardiol       Date:  2013-10-17       Impact factor: 5.952

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more
  4 in total

1.  Screening high-risk patients and selecting treatment options in stable coronary artery disease using myocardial perfusion imaging.

Authors:  Jin Chul Paeng; Dong Soo Lee
Journal:  J Nucl Cardiol       Date:  2017-01-03       Impact factor: 5.952

2.  Myocardial perfusion imaging prior to coronary revascularization: From risk stratification to procedure guidance.

Authors:  Patrick Proctor; Firas Al Solaiman; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2018-02-07       Impact factor: 5.952

3.  To quantify or not to quantify, that is the question: Semi-quantitative vs. visual analysis of Rb-82 myocardial perfusion imaging PET.

Authors:  Christoph Rischpler; David Kersting; Stephan G Nekolla
Journal:  J Nucl Cardiol       Date:  2022-03-10       Impact factor: 5.952

4.  Revascularization or medical therapy for stable coronary artery disease patients with different degrees of ischemia: a systematic review and meta-analysis of the role of myocardial perfusion.

Authors:  JingWen Yong; JinFan Tian; Xin Zhao; XueYao Yang; MingDuo Zhang; Yuan Zhou; Yi He; XianTao Song
Journal:  Ther Adv Chronic Dis       Date:  2022-01-17       Impact factor: 5.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.